An Open-label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Triheptanoin (Primary)
- Indications Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 30 Nov 2016 Results of 78-week published in an Ultragenyx Pharmaceutical media release.
- 23 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 Dec 2015 Planned end date changed from 1 Jul 2016 to 1 Sep 2016, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History